On June 30th, Skyhawk Therapeutics shared a press release with new twelve-month data from the ongoing Phase 1/2 trial of ...
In plain language. Written by scientists. For the global HD community.
SKY-0515 is a daily oral drug designed to lower both huntingtin, the protein that drives HD, and PMS1, a DNA repair protein linked to somatic CAG repeat expansion. Researchers hope this dual-target ...
In a recent study, scientists created a chemical that breaks down expanded huntingtin HTT clumps in HD cells and mouse models. This chemical finds HTT clumps and targets them to be broken down or ...
uniQure shared in a press release on June 17, 2026 that the Food and Drug Administration (FDA) has agreed the 3-year data from their Phase I/II study can serve as the basis for a Biologics License ...
In plain language. Written by scientists. The gene MSH3 is getting a lot of attention in HD research lately. New findings suggest MSH3 lowering could halt CAG repeat expansions, offering a new ...
Huntington’s disease (HD) involves the loss of cells in the striatum, an area of the brain that plays important roles in movement, cognition, and behaviour. For decades, researchers have been ...
In plain language. Written by scientists. ⏱️13 min read | Australia just made history by banning life insurers from using genetic testing against you. But for HD families in other countries, the laws ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results